Latest Conference Coverage

Donanemab Demonstrates Slowing of Alzheimer Disease Progression in Phase 3 TRAILBLAZER-ALZ 2 Trial

The clinical relevance of donanemab was demonstrated through a slowing of clinical decline, stability of clinical symptoms, lowered risk of advancement to next clinical stage, and lower risk of meaningful within-patient change.

Differences in Available Cognitive Screening Tools: Dustin Hammers, PhD

The associate professor of neurology at the Indiana University School of Medicine provided insight on the distinguishable characteristics of certain cognitive screening tools and the advantages to each. [WATCH TIME: 3 minutes]

Preparing Primary Care Centers for New Wave of Alzheimer Agents: Nicole Fowler, PhD, MHSA

The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on navigating challenges with newly approved treatments for Alzheimer disease, and using resources efficiently. [WATCH TIME: 5 minutes]

DCR Test Comparable to Other Traditional Cognitive Screening Assessments, With Less Administration Time

A comparison between impaired scores on Digital Clock and Recall and impaired scores on Montreal Cognitive Assessment produced a 76% concordance.

Caregivers Perceived Reciprocity Reduces Behavioral Symptoms in Patients With Alzheimer Disease

According to diary data, caregiver's perceived reciprocity showed a substantial direct influence on the occurrence of behavioral symptoms on both the current day and the subsequent day for patients with Alzheimer disease and related dementias.

Preclinical Research on CRISPR-Based Gene Editing for Alzheimer Disease Treatment: Brent D. Aulston, PhD

The postdoctoral fellow at the University of California San Diego discussed using CRISPR-based gene editing to alter the amyloid precursor protein gene in mice models with symptoms of Alzheimer disease. [WATCH TIME: 5 minutes]

Patient-Centric, Knowledge-Driven: Advanced Therapeutics in Movement and Related Disorders™ Congress

Clinicians must be armed with fact-based information on all treatment options especially newer medications and technologies—good clinical care must be both patient-centric and knowledge-driven.

Effect of Social Determinants of Health on Brain Aging in Minoritized Patients with Multiple Sclerosis: Cristina A.F. Román, PhD

The National Multiple Sclerosis Society sponsored research fellow at Kessler Foundation talked about a research project that investigates the differences in brain structure and aging metrics among patients with multiple sclerosis from differing racial and ethnic backgrounds. [WATCH TIME: 5 minutes]

Identifying Effective Big Data Techniques to Address Heterogeneity in Migraine: Ali Ezzati, MD

The director of the Neuroinformatics Program at the University of California, Irvine, discussed complexities with different machine learning algorithms in migraine research, including findings from the AMPP study. [WATCH TIME: 5 minutes]

Generalized Myasthenia Gravis Symptom Severity Reduced Through Ravulizumab Treatment

The highest proportions of patients with severe ocular impairment at baseline showed greater improvements in symptom severity on ravulizumab in comparison with placebo after 26 weeks.

Zilucoplan Demonstrates Consistent Efficacy in Phase 3 RAISE Study of Generalized Myasthenia Gravis

Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.

Examining Depression and Suicidality in Pediatric Patients With MS: Sarah C. Stoney, MSW, LSW

The social worker in the Pediatric Multiple Sclerosis Clinic at Children's Hospital of Philadelphia talked about depression and suicidality rates in pediatric patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Efforts Needed to Reach Underserved Communities, Advance Pain Medicine Research: Burel Goodin, PhD

The professor of anesthesiology at Washington University in St. Louis discussed the reasons behind his presentation at the 2023 AHS Annual Meeting on engaging underserved populations in pain medicine research. [WATCH TIME: 3 minutes]

Enhancing Caregiver and Patient Wellbeing Through a Physical Activity Intervention: Afolasade Fakolade, PhD

The assistant professor at Queen’s University discussed results from a pilot trial that evaluated the impact of a dyadic physical activity intervention among both caregivers and patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Ketogenic Agent Tricaprilin Shows Potential Benefit in Pilot Study of Migraine

At month 2 of a 3-month treatment period, investigators observed an improvement of 2.75 days favoring tricaprilin.

Subanalysis of ADAPT Reveals Consistent Efficacy With Efgartigimod Among All Genders

Patients with generalized myasthenia gravis treated with efgartigimod consistently exceeded treatment compared with placebo regardless of gender in age, disease duration, BMI, and thymectomy.

Dedicated Efforts for Improving Sleep Quality in Pediatrics, Adolescents: Sarah Honaker, PhD; Maureen McQuillan, PhD

The duo from Indiana University School of Medicine discussed the ongoing research initiatives to better understand sleep disorders among pediatrics, and ways to improve approaches like cognitive behavioral therapy. [WATCH TIME: 4 minutes]

Exploring the Impact of Indole-3-Lactate in the Gut-Brain Axis and Multiple Sclerosis: Larissa Jank, MD

Finding More Creative and Effective Ways to Teach Neurology: Alexandria Reynolds, PhD

The undergraduate program director at the University of South Carolina discussed outdated teaching methods used in neurology, and the need to provide different hands-on approaches to students. [WATCH TIME: 5 minutes]

Prospects for Improving Cognitive Impairment in Early MS With Ozanimod: Robert Zivadinov, MD, PhD

The director of the Buffalo Neuroimaging Analysis Center talked about the ENLIGHTEN trial, where results showed a correlation between cognitive impairment and brain volume with ozanimod. [WATCH TIME: 5 minutes]

Migraine Preventive Atogepant Effective in Individuals With Prior Medication Failures

In a cohort of patients who experienced 4-14 migraine days/month, treatment with atogepant continued to improve patients’ migraine status regardless of prior medication failures.

BTK Inhibitor Remibrutinib Demonstrates Positive Safety in Various Autoimmune Disorders

Findings from data on patients with various autoimmune disorders who used remibrutinib, a BTK inhibitor in development for multiple sclerosis, reported no safety concerns in laboratory analyses.

Unraveling the Complexity of Fatigue in Multiple Sclerosis: John DeLuca, PhD

The senior vice president for Research and Training at Kessler Foundation talked about the issue of fatigue in patients with multiple sclerosis and the significant, multifaceted challenges patients face. [WATCH TIME: 5 minutes]

Need for Adaptation of Cognitive Behavioral Therapy for Adolescents With Insomnia: Sarah Honaker, PhD; Maureen McQuillan, PhD

The duo from Indiana University School of Medicine provided perspective on the reasons for why cognitive behavioral therapy used for insomnia need to be adjusted in adolescents with the sleep disorder. [WATCH TIME: 3 minutes]

Diroximel Fumarate Maintains Efficacy in Elderly Populations of Multiple Sclerosis

Over a 96-week period, more older patients with relapsing multiple sclerosis on diroximel fumarate achieved no evidence of disease activity-3 status vs younger patients.

Significant Associations Identified Between MRI Biomarkers and Clinical Functions in MS

In the phase 3 OPTIMUM study of ponesimod, findings showed that MRI features in patients with multiple sclerosis were significantly associated with clinical scales.

Neurological Examination and Guiding Clinicians in the Diagnosis of Multiple Sclerosis: Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

The assistant professor at Hunter College discussed the approach of systematically localizing symptoms in patients with multiple sclerosis for diagnosis based on a clinical workshop. [WATCH TIME: 5 minutes]

Navigating the Transition From Pediatric to Adult MS Care: Yolanda Wheeler, PhD, CPNP-AC, MSCN

The assistant professor at the University of Alabama at Birmingham discussed the transition from pediatric to adult care for patients with multiple sclerosis as well as the challenges presented in diagnosis, treatment, and understanding the long-term impact of the disease. [WATCH TIME: 5 minutes]

New Approaches and Guidelines for Essential Tremor in Movement Disorders: David Shprecher, DO, MSci, FAAN

The director of movement disorders at the Banner Sun Health Research Institute talked about how research in essential tremor is revolutionizing the diagnosis and understanding of the movement disorder. [WATCH TIME: 5 minutes]

Burel Goodin, PhD, on Building Trust in Underserved Communities to Improve Clinical Trial Outcomes

The professor of anesthesiology at Washington University in St. Louis discussed the importance of effectively communicating and reciprocating with underserved communities that are of research interest.